Table 2.
Efficiency of the different formulations against M. tuberculosis H37Rv-GFP extracellular or intramacrophage replication.
| Formulation | Extracellular assay IC50 (µg/mL) ± SD | Intracellular assay IC50 (µg/mL) ± SD | |
|---|---|---|---|
| Controls (DMSO) | ETH | 0.30 ± 0.10 | 0.11 ± 0.01 |
| [ETH:Booster] | 0.11 ± 0.06 | 0.06 ± 0.02 | |
| PLA NPs (Nanoemulsion) | PLA::ETH | 0.12 ± 0.04 | 0.09 ± 0.05 |
| PLA::[ETH:Booster] | 0.06 ± 0.02 | 0.04 ± 0.02 | |
| pCD NPs | pCD::ETH | 0.13 ± 0.04 | 0.06 ± 0.01 |
| pCD::[ETH:Booster] | 0.06 ± 0.02 | 0.04 ± 0.01 | |
Results, expressed as concentration of ETH required to inhibit 50% of the bacterial growth in µg/mL (IC50), were calculated by nonlinear regression analysis using the equation for a sigmoidal dose-response curve with variable slope using the GraphPad Prism 5.0 software. Results are shown as the mean ± standard deviation of three independent experiments.